Waverley Pharma Inc.
WAVE.V
TSX
| 03/31/2026 | 09/30/2025 | 06/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -24.28% | 1,120.12% | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -24.28% | 1,120.12% | -- | -- | -- |
| Cost of Revenue | -19.77% | 2,536.84% | -- | -- | -- |
| Gross Profit | -32.09% | 366.36% | -- | -- | -- |
| SG&A Expenses | 38.19% | 236.29% | 24.75% | 24.75% | -5.62% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.97% | 82.80% | 21.99% | 21.99% | 71.03% |
| Operating Income | -544.53% | 18.53% | 103.33% | 103.33% | 91.82% |
| Income Before Tax | -374.10% | 14.24% | 92.02% | 92.02% | 87.19% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -374.10% | 13.64% | 92.02% | 92.02% | 87.19% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -374.10% | 13.64% | 92.02% | 92.02% | 87.19% |
| EBIT | -544.53% | 18.53% | 103.33% | 103.33% | 91.82% |
| EBITDA | -6,233.33% | 27.07% | 113.63% | 113.63% | 101.11% |
| EPS Basic | -340.00% | 13.51% | 91.49% | 91.49% | 86.11% |
| Normalized Basic EPS | -366.67% | 13.04% | 93.10% | 93.10% | 86.96% |
| EPS Diluted | -340.00% | 56.16% | 94.52% | 94.52% | 86.11% |
| Normalized Diluted EPS | -366.67% | 13.04% | 93.10% | 93.10% | 86.96% |
| Average Basic Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Average Diluted Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |